An international, biomarker-directed, randomized, phase II trial of AZD1775 plus paclitaxel and carboplatin (P/C) for the treatment of women with platinum-sensitive, TP53-mutant ovarian cancer.

Sistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSPOZA, Amit M.WEBERPALS, Johanne IngridPROVENCHER, Diane M.GRISCHKE, Eva-MariaHALL, MarciaUYAR, DeniseESTEVEZ-DIZ, Maria Del PilarMARME, FrederikKUZMIN, AlexeyROSENBERG, PerWENHAM, Robert MichaelQIU, JingjunLEE, Mark AnthonyLIU, JiROSE, ShelonitdaMOORE, Kathleen N.2015-11-112015-11-112015JOURNAL OF CLINICAL ONCOLOGY, v.33, n.15, suppl.S, 20150732-183Xhttps://observatorio.fm.usp.br/handle/OPI/12231engrestrictedAccessAn international, biomarker-directed, randomized, phase II trial of AZD1775 plus paclitaxel and carboplatin (P/C) for the treatment of women with platinum-sensitive, TP53-mutant ovarian cancer.conferenceObjectCopyright AMER SOC CLINICAL ONCOLOGYOncology1527-7755